HealthInvest Partners AB Grows Holdings in DexCom, Inc. (NASDAQ:DXCM)

HealthInvest Partners AB lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 11.7% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 60,057 shares of the medical device company’s stock after acquiring an additional 6,300 shares during the period. DexCom makes up 2.2% of HealthInvest Partners AB’s investment portfolio, making the stock its 17th biggest position. HealthInvest Partners AB’s holdings in DexCom were worth $4,684,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Versant Capital Management Inc bought a new position in DexCom during the fourth quarter valued at approximately $25,000. Heck Capital Advisors LLC bought a new position in shares of DexCom during the 4th quarter valued at $38,000. Midwest Capital Advisors LLC bought a new position in shares of DexCom during the 4th quarter valued at $54,000. MassMutual Private Wealth & Trust FSB raised its position in DexCom by 46.7% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock worth $65,000 after purchasing an additional 265 shares during the period. Finally, RPg Family Wealth Advisory LLC bought a new stake in DexCom in the third quarter worth $57,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the business’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the sale, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the sale, the executive vice president now directly owns 83,526 shares in the company, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 38,083 shares of company stock worth $3,309,794. 0.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Canaccord Genuity Group raised their target price on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Finally, Wells Fargo & Company upped their price target on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $99.06.

DexCom Trading Down 0.6 %

NASDAQ DXCM opened at $88.78 on Monday. The stock’s 50 day moving average is $83.50 and its 200 day moving average is $76.06. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $34.69 billion, a PE ratio of 62.08, a P/E/G ratio of 2.30 and a beta of 1.14. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.